Schizophrenia biomarkers: translating the descriptive into the diagnostic

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Biology

Background:

• Schizophrenia and mental health disorders have distinct clinical presentations but overlapping molecular underpinnings.
• Biomarker identification in schizophrenia aims to improve illness prediction, diagnostic clarity, and treatment guidance.
• The optimal sample types and analytical methods for biomarker discovery are still under investigation.

Purpose of the Study:

• To review recent advances in biomarker identification for schizophrenia across various technical approaches.
• To evaluate the strengths and weaknesses of different methods used in biomarker research.
• To suggest reasons for the limited success in finding robust biomarkers and propose new strategies.

Main Methods:

• Comprehensive review of recent scientific literature on schizophrenia biomarker studies.
• Analysis of studies employing diverse technical platforms, including '-omics' datasets.
• Comparative assessment of the methodologies and their contributions to understanding disease pathology.

Main Results:

• Recent studies have significantly enhanced the understanding of schizophrenia's pathological processes.
• Despite advances, robust and clinically applicable biomarkers for schizophrenia have not yet been established.
• The review highlights the gap between understanding disease mechanisms and developing practical biomarkers.

Conclusions:

• Current research provides valuable insights into schizophrenia's molecular pathology but has yet to yield definitive biomarkers.
• Challenges in sample selection and analytical techniques may hinder biomarker discovery.
• Future strategies should focus on novel approaches for extracting biomarkers from large '-omics' data to aid clinical applications.